Insulet Corporation

XNASHealth care

Last traded price · USD

$167.00

+7.84%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 04:52 IST · A quote does not mean the product is available to trade on your account.

Day's open: $148.61
Previous close: $154.86
Volume: 2.6M
Day's high: $165.46
Day's low: $148.55

In brief

Insulet Corporation is a health care company listed on Nasdaq, valued at about $11.58B.
Its shares closed at $165.02 on 4 Nov 2026, down 48.5% over the past year.
From India you can buy PODD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Insulet Corporation (PODD) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PODD share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PODD options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +22.5% (SPY −1.6%, XLV +13.5%). 3 months: +23.8% (SPY −0.4%, XLV +15.5%). 1 year: −48.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PODD, SPY and XLV · as of 4 Nov 2026
RSI(14) at 77.1, 70 or above
The 14-session relative strength index closed at 77.1 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $165.02 was 16.5% above its 50-day average ($141.65) and 6.7% below its 200-day average ($176.87). It has closed below the 200-day for 229 sessions, since 8 Dec 2025. The 50-day average crossed below the 200-day on 20 Jan 2026, 200 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
17% of the way up its 52-week range
Closed at $165.02 on 4 Nov 2026: 53.5% below the 52-week high of $354.88 (20 Nov 2025) and 30.6% above the low of $126.40 (5 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.7× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.6M shares was 1.7× the average of the 30 sessions before it (1.5M), as the price rose 6.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+22.5%

6 months+9.1%

1 year−48.5%

5 years−45.3%

Newswire

About

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Website

Notable moves

August 5, 2026
−20.12%
May 9, 2025
+20.88%
November 4, 2022
+22.58%

Insulet Corporation

XNASHealth care

Last traded price · USD

$167.00

+7.84%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 04:52 IST · A quote does not mean the product is available to trade on your account.

Day's open: $148.61
Previous close: $154.86
Volume: 2.6M
Day's high: $165.46
Day's low: $148.55

In brief

Insulet Corporation is a health care company listed on Nasdaq, valued at about $11.58B.
Its shares closed at $165.02 on 4 Nov 2026, down 48.5% over the past year.
From India you can buy PODD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Insulet Corporation (PODD) shares from India?

Do I need the price of a whole PODD share to invest?

How much can I invest in US stocks in a year?

Can I trade PODD options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +22.5% (SPY −1.6%, XLV +13.5%). 3 months: +23.8% (SPY −0.4%, XLV +15.5%). 1 year: −48.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PODD, SPY and XLV · as of 4 Nov 2026
RSI(14) at 77.1, 70 or above
The 14-session relative strength index closed at 77.1 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $165.02 was 16.5% above its 50-day average ($141.65) and 6.7% below its 200-day average ($176.87). It has closed below the 200-day for 229 sessions, since 8 Dec 2025. The 50-day average crossed below the 200-day on 20 Jan 2026, 200 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
17% of the way up its 52-week range
Closed at $165.02 on 4 Nov 2026: 53.5% below the 52-week high of $354.88 (20 Nov 2025) and 30.6% above the low of $126.40 (5 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.7× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.6M shares was 1.7× the average of the 30 sessions before it (1.5M), as the price rose 6.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+22.5%

6 months+9.1%

1 year−48.5%

5 years−45.3%

Newswire

About

Website

Notable moves

August 5, 2026
−20.12%
May 9, 2025
+20.88%
November 4, 2022
+22.58%

Insulet Corporation

Insulet Corporation in brief

Behind SPY and its sector fund XLV over 1 year

RSI(14) at 77.1, 70 or above

Above its 50-day average, below its 200-day

17% of the way up its 52-week range

Volume 1.7× its 30-session average on 4 Nov 2026

Insulet Corporation

Insulet Corporation in brief

Behind SPY and its sector fund XLV over 1 year

RSI(14) at 77.1, 70 or above

Above its 50-day average, below its 200-day

17% of the way up its 52-week range

Volume 1.7× its 30-session average on 4 Nov 2026